CSL Limited (CSJ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CSL Limited (CSJ) has a cash flow conversion efficiency ratio of 0.045x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€810.25 Million) by net assets (€17.83 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CSL Limited - Cash Flow Conversion Efficiency Trend (2014–2023)
This chart illustrates how CSL Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CSL Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CSL Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Occidental Petroleum Corporation
NYSE:OXY
|
0.076x |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
0.222x |
|
Great-West Lifeco Inc.
TO:GWO
|
-0.010x |
|
COMPASS GROUP
F:XGR
|
N/A |
|
RIO Tinto Ltd
AU:RIO
|
0.151x |
|
Maruti Suzuki India Limited
NSE:MARUTI
|
0.050x |
|
Axis Bank Limited
NSE:AXISBANK
|
-0.074x |
|
Fannie Mae
LSE:0IL0
|
0.085x |
Annual Cash Flow Conversion Efficiency for CSL Limited (2014–2023)
The table below shows the annual cash flow conversion efficiency of CSL Limited from 2014 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | €17.83 Billion | €2.60 Billion | 0.146x | -19.09% |
| 2022-06-30 | €14.58 Billion | €2.63 Billion | 0.180x | -58.27% |
| 2021-06-30 | €8.38 Billion | €3.62 Billion | 0.432x | +65.18% |
| 2020-06-30 | €9.51 Billion | €2.49 Billion | 0.262x | +19.13% |
| 2019-06-30 | €7.49 Billion | €1.64 Billion | 0.220x | -36.27% |
| 2018-06-30 | €5.52 Billion | €1.90 Billion | 0.345x | +13.69% |
| 2017-06-30 | €4.11 Billion | €1.25 Billion | 0.303x | -11.10% |
| 2016-06-30 | €3.46 Billion | €1.18 Billion | 0.341x | -31.32% |
| 2015-06-30 | €2.75 Billion | €1.36 Billion | 0.496x | +15.36% |
| 2014-06-30 | €3.16 Billion | €1.36 Billion | 0.430x | -- |
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more